These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21832894)

  • 1. Combination therapy for dyslipidemia.
    Sharma M
    Curr Opin Cardiol; 2011 Sep; 26(5):420-3. PubMed ID: 21832894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials.
    Michos ED; Sibley CT; Baer JT; Blaha MJ; Blumenthal RS
    J Am Coll Cardiol; 2012 Jun; 59(23):2058-64. PubMed ID: 22520249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ezetimibe and recent clinical trials: a look on the bright side.
    Ahmed MH
    Expert Opin Drug Saf; 2010 Jul; 9(4):511-4. PubMed ID: 20377476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation.
    Crespo-Leiro MG; Paniagua MJ; Marzoa R; Grille Z; Naya C; Flores X; Rodriguez JA; Mosquera V; Franco R; Castro-Beiras A
    Transplant Proc; 2008 Nov; 40(9):3060-2. PubMed ID: 19010194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal pharmacotherapy to combat the atherogenic lipid triad.
    Chapman MJ; Redfern JS; McGovern ME; Giral P
    Curr Opin Cardiol; 2011 Sep; 26(5):403-11. PubMed ID: 21730827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.
    Ahmed MH; Khalil AA
    Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1021-9. PubMed ID: 21060168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR; Knight M
    Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.
    Chapman MJ; Redfern JS; McGovern ME; Giral P
    Pharmacol Ther; 2010 Jun; 126(3):314-45. PubMed ID: 20153365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors].
    Broncel M; Balcerak M; Chojnowska-Jezierska J
    Pol Merkur Lekarski; 2007 Jan; 22(127):62-5. PubMed ID: 17477094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
    Bajnok L
    Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical use of ezetimibe.
    Cheng AY; Leiter LA
    Can J Clin Pharmacol; 2003; 10 Suppl A():21A-5A. PubMed ID: 14571302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multimodal therapy of dyslipidemia].
    Stahn A; Hanefeld M
    Clin Res Cardiol Suppl; 2011 May; 6():10-6. PubMed ID: 22528173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin and ezetimibe combination therapy in cardiovascular disease.
    Dembowski E; Davidson MH
    Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):183-8. PubMed ID: 19262375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders.
    Vo AN; Kashyap ML
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1303-10. PubMed ID: 19018682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH).
    AIM-HIGH Investigators
    Am Heart J; 2011 Mar; 161(3):471-477.e2. PubMed ID: 21392600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy.
    Charland SL; Malone DC
    Curr Med Res Opin; 2010 Feb; 26(2):365-75. PubMed ID: 19995326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.